Research in young people at ultra-high risk for psychosis: A review of the current evidence

Irish Journal of Psychological Medicine

Volumn 30, Issue 1, 2013, Pages 77-89

  O'connor, K ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Pre psychotic; prodrome; psychosis; schizophrenia; ultra high risk

Indexed keywords

EID: 85010636166     PISSN: 07909667     EISSN: 20516967     Source Type: Journal    
DOI: 10.1017/ipm.2012.9     Document Type: Review

References (75)

1. Addington J, Epstein I, Liu L, French P, Boydell KM, Zipursky RB (2011). A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research 125, 54–61.
2. Amminger PG, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE (2010). Long chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomised placebo-controlled trial. Archives of General Psychiatry 67, 146–154.
3. Auther AM, et al. (2008). Presented at the 63rd Annual Meeting of the Society of Biological Psychiatry, Washington, DC, May 2008.
4. Bechdolf A, Pukrop R, Kohn D, Tschinkel S, Veith V, Schultze-Lutter F, Ruhrmann S, Geyer C, Pohlmann B, Klosterkotter J (2005). Subjective quality of life in subjects at risk of psychosis in Germany: concept and recruitment. Schizophrenia Research 79, 137–143.
5. Bechdolf A, Wagner M, Ruhrmann S, Harrigan S, Putzfeld V, Pukrop R, Brockhaus-Dumke A, Berning J, Janssen B, Decker P, Bottlender R, Maurer K, Möller HJ, Gaebel W, Häfner H, Maier W, Klosterkötter J (2012). Preventing progression to first-episode psychosis in early initial prodromal states. British Journal of Psychiatry 200, 22–29.
6. Bertelsen M, Jeppesen P, Petersen L, Thorup A, Øhlenschlaeger J, le Quach P, Christensen TØ, Krarup G, Jørgensen P, Nordentoft M (2008). Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Archives of General Psychiatry 65, 762–771.
7. Binbay T, Drukker M, Elbi H, Tanık FA, Özkinay F, Onay H, Zaǧli N, van Os J, Alptekin L (2011). Testing the psychosis continuum: differential impact of genetic and nongenetic risk factors and comorbid psychopathology across the entire spectrum of psychosis. Schizophrenia Bulletin. epub ahead of print
8. Birchwood M, Trower P (2006). The future of cognitive-behavioural therapy for psychosis: not a quasi-neuroleptic. British Journal of Psychiatry 188, 107–108.
9. Birchwood M, Smith J, Macmillan F (1989). Cognitive therapy for the prevention of psychosis in people at ultra high risk for psychosis: randomised system using patients and families as observers. Psychological Medicine 19, 649–656.
10. Bowers MB (1965). The onset of psychosis – a diary account. Psychiatry 28, 346–358.
11. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R (2008). Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry 65, 28–37.
12. Clarke M, Whitty P, Browne S, McTigue O, Kamali M, Gervin M, Kinsella A, Waddington JL, Larkin C, O'Callaghan E (2006). Untreated illness and outcome of psychosis. British Journal of Psychiatry 189, 235–240.
13. Corcoran CM, First MB, Cornblatt B (2010). The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk–benefit analysis. Schizophrenia Research 120, 16–22.
14. Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gervin M, et al. (2009). Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. British Journal of Psychiatry 194, 18–24.
15. Dominguez MD, Wichers M, Lieb R, Wittchen HU, van Os J (2011). Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study. Schizophrenia Bulletin 37, 84–93.
16. DSM Task Force (2012). American Psychiatric Association. (http://www.dsm5.org/about/Pages/DSMVOverview.aspx). Accessed 12 April 2012.
17. DSM Task Force (2012). American Pschiatric Association. (http://www.dsm5.org/proposedRevisions/Pages/proposedrevision.aspx?rid=412). Accessed 1 July 2012.
18. Foley D, Morley K (2011). Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Archives of General Psychiatry 68, 609–616.
19. Fornito A, Yung AR, Wood SJ, Phillips LJ, Nelson B, Cotton S, Velakoulis D, McGorry PD, Pantelis C, Yücel M (2008). Anatomic abnormalities of the anterior cingulate cortex before psychosis onset: an MRI study of ultra-high-risk individuals. Biological Psychiatry 64, 758–765.
20. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P (2012). Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry 69, 220–229.
21. Giuliano AJ, Li H, Mesholam-Gately RI, Sorenson SM, Woodberry KA, Seidman LJ (2012). Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Current Pharmaceutical Design 18, 399–415.
22. Gross G, Huber G, Klosterkötter J, Linz M (1987). BSABS, Bonner Skala für die Beurteilung von Basissymptomen, Bonn Scale for the Assessment of Basic Symptoms. Springer: Berlin, Heidelberg, New York.
23. Gumley AI, O'Grady M, McNay L, Reilly J, Power K, Norrie J (2003). Early intervention for relapse in schizophrenia: results of a 12-month randomised controlled trial of cognitive behaviour therapy. Psychological Medicine 33, 419–431.
24. Hafner H, Maurer K, Loffler W, Bustamante S, an der Heiden W, Riecher-Rossler A, Nowotny B (1995). Onset and early course of schizophrenia. In Search for the Cause of Schizophrenia, Vol. 3 (ed. H. G. W. Hafner), pp. 43–66. Springer-Verlag: Berlin.
25. Haroun N, Dunn L, Haroun A, Cadenhead KS (2006). Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophrenia Bulletin 32, 166–178.
26. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G (1994). One hundred years of schizophrenia: a meta analysis of the outcome literature. American Journal of Psychiatry 151, 1409–1416.
27. Henry LP, Amminger GP, Harris MG, Yuen HP, Harrigan SM, Prosser AL, et al. (2010). The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. The Journal of Clinical Psychiatry 71, 716–728.
28. Kelleher I, Connor D, Clarke MC, Devlin N, Harley M, Cannon M (2012 a). Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychological Medicine. ePub ahead of print
29. Kelleher I, Keeley H, Corcoran P, Lynch F, Fitzpatrick C, Devlin N, Molloy C, Roddy S, Clarke MC, Harley M, Arseneault L, Wasserman C, Carli V, Sarchiapone M, Hoven C, Wasserman D, Cannon M (2012 b). Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies. British Journal of Psychiatry. ePub ahead of print
30. Klosterkotter J, Hellmich M, Steinmyer E (2001). Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry 58, 158–164.
31. Larsen TK, Johannssem JO, Opjordsmoen S (1998). First-episode schizophrenia with long duration of untreated psychosis. Pathways to care. British Journal of Psychiatry 172, 45–52.
32. Marshall M, Rathbone J (2011). Early intervention for psychosis. Cochrane Database of Systematic Reviews, Issue 6. Art. No.: CD004718.
33. McGlashan TH, Johannessen JO (1996). Early detection and intervention with schizophrenia: rationale. Schizophrenia Bulletin 22, 201–222.
34. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163, 790–799.
35. McGorry PD, Yung AR, Philips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H (2002). Randomised controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with sub-threshold symptoms. Archives of General Psychiatry 59, 921–928.
36. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey S, Berger G, Riecher-Rössler A, Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Nordentoft M, Hickie I, McGuire P, Berk M, Chen EY, Keshavan MS, Yung AR (2009). Intervention in individuals at ultra high risk for psychosis: a review and future directions. The Journal of Clinical Psychiatry 70, 1206–1212.
37. Meares A (1959). The diagnosis of pre-psychotic schizophrenia. Lancet 10, 55–58.
38. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, Woods SW (2002). Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry 159, 863–865.
39. Morrison AP, French P, Parker S (2007). Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin 33, 682–687.
40. Morrison A, French P, Parker S, Roberts M, Stevens H, Bentall RP, Lewis SW (2007). Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultra high risk. Schizophrenia Bulletin 33, 682–687.
41. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP (2004). Cognitive therapy for the prevention of psychosis in people at ultra high risk for psychosis: randomised control trial. British Journal of Psychiatry 185, 291–297.
42. Morrison AP, French P, Stewart S, Birchwood M, Fowler D, Gumley AI, Jones PB, Bentall RP, Lewis SW, Murray GK, Patterson P, Brunet K, Conroy J, Parker S, Reilly T, Byrne R, Davies LM, Dunn G (2012). Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ, Apr 5;344:e2233.
43. Olsen KA, Rosenbaum B (2006). Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatrica Scandinavica 113, 247–272.
44. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Philips LJ, et al. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 25, 281–288.
45. Philips LJ, Yung AR, McGorry PD (2000). Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Australian and New Zealand Journal of Psychiatry 34, 5164–5169.
46. Phillips LJ, Curry C, Yung AR, Yuen HP, Adlard S, McGorry PD (2002). Cannabis use is not associated with the development of psychosis in an ‘ultra’ high-risk group. Australian and New Zealand Journal of Psychiatry 36, 800–806.
47. Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D, Francey SM, Yung AR (2007). Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophrenia Research 96, 25–33.
48. Raven M, Stuart GW, Jureidini J (2012). ‘Prodromal’ diagnosis of psychosis: ethical problems in research and clinical practice. Australian and New Zealand Journal of Psychiatry 46, 64–65.
49. Ruhrmann S, Bechdolf A, Kühn KU, Wagner M, Schultze-Lutter F, Janssen B, Maurer K, Häfner H, Gaebel W, Möller HJ, Maier W, Klosterkötter J (2007). Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. British Journal of Psychiatry 191, S88–S95.
50. Ruhrmann S, Schultze-Lutter F, Salokangangas RK, Heinmaa M, Linszen D, Dingemans P, Birchwood M, Patterson P, Juckel G, Heinz A, Morrison A, Lewis S, von Reventlow HG, Klosterkötter J (2010). Prediction of psychosis in adolescents and young adults at high risk; results from the prospective European prediction of psychosis study. Archives of General Psychiatry 67, 241–251.
51. Schaffner K, McGorry PD (2001). Preventing severe mental illnesses – new prospects and ethical challenges. Schizophrenia Research 51, 3–15.
52. Schultze-Lutter F (2009). Subjective symptoms of schizophrenia in research and the clinic: the basic symptoms concept. Schizophrenia Bulletin 35, 5–8.
53. Schultze-Lutter F, Ruhrmann S, Picker H, Klosterkotter J (2007). The Schizophrenia Proneness Instrument (SPI-A) – a tool for the assessment of basic symptoms. European Psychiatry 21, s27.
54. Schultze-Lutter F, Ruhrmann S, Hoyer C, Klosterkotter J, Leweke FM (2007). The initial prodrome of schizophrenia: different duration, different underlying deficits? Comprehensive Psychiatry 48, 479–488.
55. Sullivan HS (1927). The onset of schizophrenia. American Journal of Psychiatry 151, 135–139.
56. Tandon R, Nasrallah HA, Keshavan MS (2009). Schizophrenia, ‘just the facts’ 4. Clinical features and conceptualization. Schizophrenia Research 110, 1–23.
57. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L (2009). A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychological Medicine 39, 179–195.
58. Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, Smith D, Brewer W, Proffitt T, Desmond P, Pantelis C (2006). Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Archives of General Psychiatry 63, 139–149.
59. Walker EF, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Heinssen R (2009). The relation of antipsychotic and antidepressant medication with baseline symptoms and symptoms progression: a naturalistic study of the North American prodrome longitudinal sample. Schizophrenia Research 115, 50–57.
60. Warner R (2002). Limitations of the Bonn Scale for the assessment of basic symptoms as a screening measure. Archives of General Psychiatry 59, 470–471.
61. Woodberry KA, Seidman LJ, Giuliano AJ, Verdi MB, Cook WL, McFarlane WR (2010). Neuropsychological profiles in individuals at clinical high risk for psychosis: relationship to psychosis and intelligence. Schizophrenia Research 123, 188–198.
62. Woods SW, Walsh BC, Saksa JR, McGlashan TH (2010). The case for including Attenuated Psychotic Symptoms Syndrome in DSM-5 as a psychosis risk syndrome. Schizophrenia Research 123, 199–207.
63. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH (2003). Randomised trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry 54, 453–464.
64. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, et al. (2009). Validity of the prodromal risk syndrome for psychosis: findings from the North American Prodrome Longitudinal Study. Schizophrenia Bulletin 35, 894–908.
65. Wyatt R, Henter I (2001). Rationale for the study of early intervention. Schizophrenia Research 51, 69–76.
66. Yung AR, McGorry PD (1996). The prodromal phase of first episode psychosis: past and current conceptualisations. Schizophrenia Bulletin 22, 353–370.
67. Yung AR, Nelson B (2011). Young people at ultra high risk for psychosis: a research update. Early Intervention in Psychiatry 5, 52–57.
68. Yung AR, Philips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD (2000). Psychosis prediction: 12 month follow up of a high risk (‘prodromal’) group. Schizophrenia Research 60, 21–32.
69. Yung AR, Philips LJ, Yuen HP, McGorry PD (2004). Risk factors for psychosis in an ultra high risk group: psychopathology and clinical features. Schizophrenia Research 67, 131–142.
70. Yung AR, Phillips LJ, Yuen HP (2004). Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophrenia Research 67, 131–142.
71. Yung A, Nelson B, Thompson A, Wood SJ (2010). The psychosis threshold in ultra high risk (prodromal) research: is it valid? Schizophrenia Research 120, 1–3.
72. Yung AR, Nelson B, Thompson AD, Wood SJ (2010). Should a ‘Risk Syndrome for Psychosis’ be included in the DSMV? Schizophrenia Research 120, 7–15.
73. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell-Olio M, et al. (2005). Mapping the onset of psychosis: The Comprehensive Assessment of At Risk Mental States (CAARMS). Australian and New Zealand Journal of Psychiatry 39, 964–971.
74. Yung AR, Yuen HP, Berger G, Francey S, Hung T, Nelson B, et al. (2007). Declining transition rate in ultra high risk (prodromal) services: dilution or redirection of risk? Schizophrenia Bulletin 33, 673–681.
75. Yung AR, Phillips LJ, Nelson B, Francey SM, PanYuen H, Simmons MB et al. (2011). Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. Journal of Clinical Psychiatry 72, 430–440.